This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n4http://linked.opendata.cz/resource/domain/vavai/subjekt/
n3http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n6http://linked.opendata.cz/ontology/domain/vavai/riv/
n18http://bibframe.org/vocab/
n16http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F12%3A%230001654%21RIV13-MZ0-65269705/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F65269705%3A_____%2F12%3A%230001654%21RIV13-MZ0-65269705
rdf:type
skos:Concept n3:Vysledek
dcterms:description
Recent evidence suggests that - in addition to 17p deletion - TP53 mutation is an independent prognostic factor in chronic lymphocytic leukemia (CLL). Data from retrospective analyses and prospective clinical trials show that ~5% of untreated CLL patients with treatment indication have a TP53 mutation in the absence of 17p deletion. These patients have a poor response and reduced progression-free survival and overall survival with standard treatment approaches. These data suggest that TP53 mutation testing warrants integration into current diagnostic work up of patients with CLL. There are a number of assays to detect TP53 mutations, which have respective advantages and shortcomings. Direct Sanger sequencing of exons 4-9 can be recommended as a suitable test to identify TP53 mutations for centers with limited experience with alternative screening methods. Recommendations are provided on standard operating procedures, quality control, reporting and interpretation. Patients with treatment indications should be investigated for TP53 mutations in addition to the work-up recommended by the International workshop on CLL guidelines. Patients with TP53 mutation may be considered for allogeneic stem cell transplantation in first remission. Alemtuzumab-based regimens can yield a substantial proportion of complete responses, although of short duration. Ideally, patients should be treated within clinical trials exploring new therapeutic agents. Recent evidence suggests that - in addition to 17p deletion - TP53 mutation is an independent prognostic factor in chronic lymphocytic leukemia (CLL). Data from retrospective analyses and prospective clinical trials show that ~5% of untreated CLL patients with treatment indication have a TP53 mutation in the absence of 17p deletion. These patients have a poor response and reduced progression-free survival and overall survival with standard treatment approaches. These data suggest that TP53 mutation testing warrants integration into current diagnostic work up of patients with CLL. There are a number of assays to detect TP53 mutations, which have respective advantages and shortcomings. Direct Sanger sequencing of exons 4-9 can be recommended as a suitable test to identify TP53 mutations for centers with limited experience with alternative screening methods. Recommendations are provided on standard operating procedures, quality control, reporting and interpretation. Patients with treatment indications should be investigated for TP53 mutations in addition to the work-up recommended by the International workshop on CLL guidelines. Patients with TP53 mutation may be considered for allogeneic stem cell transplantation in first remission. Alemtuzumab-based regimens can yield a substantial proportion of complete responses, although of short duration. Ideally, patients should be treated within clinical trials exploring new therapeutic agents.
dcterms:title
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
skos:prefLabel
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
skos:notation
RIV/65269705:_____/12:#0001654!RIV13-MZ0-65269705
n3:predkladatel
n4:ico%3A65269705
n6:aktivita
n10:V n10:I
n6:aktivity
I, V
n6:cisloPeriodika
7
n6:dodaniDat
n7:2013
n6:domaciTvurceVysledku
n15:1957864 n15:2093995 n15:4629604
n6:druhVysledku
n13:J
n6:duvernostUdaju
n11:S
n6:entitaPredkladatele
n16:predkladatel
n6:idSjednocenehoVysledku
134676
n6:idVysledku
RIV/65269705:_____/12:#0001654
n6:jazykVysledku
n17:eng
n6:klicovaSlova
chronic lymphocytic leukemia
n6:klicoveSlovo
n14:chronic%20lymphocytic%20leukemia
n6:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n6:kontrolniKodProRIV
[81B39FCC67A2]
n6:nazevZdroje
Leukemia
n6:obor
n12:FD
n6:pocetDomacichTvurcuVysledku
3
n6:pocetTvurcuVysledku
17
n6:rokUplatneniVysledku
n7:2012
n6:svazekPeriodika
26
n6:tvurceVysledku
Trbušek, Martin Malčíková, Jitka Pospíšilová, Šárka
n6:wos
000306307600003
s:issn
0887-6924
s:numberOfPages
4
n18:doi
10.1038/leu.2012.25